> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Former FDAer John Jenkins Joins Corbus Board
- URL: https://www.fdaweb.com/former-fdaer-john-jenkins-joins-corbus-board/
- Published: 2018-06-06T12:00:00.000Z
- Updated: 2026-09-15T00:11:14.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5141615

**John Jenkins**, the former head of CDER’s Office of New Drugs, who left the agency following a [public dust-up](https://www.fdaweb.com/jenkins-delayed-retirement-to-protect-drug-reviews-from-woodcock/) with Center director **Janet Woodcock** over approval of Sarepta’s Duchenne muscular dystrophy drug Exondys 51 (eteplirsen), is joining the board of Corbus Pharmaceuticals. Endpoints News [reports](https://endpts.com/fda-vet-and-woodcock-nemesis-john-jenkins-is-stepping-over-to-a-new-role-as-a-board-member-at-corbus-pharma/?ref=fdaweb.com) that Corbus is in a Phase 3 trial of its lenabasum in systemic sclerosis and a Phase 2b trial in cystic fibrosis, among other programs.

Since leaving FDA, Jenkins as been working at Greenleaf Health, an FDA-focused strategic consulting firm, Endpoints says. Corbus is the first drug company board seat he has accepted.

In the dispute over Exondys 51 approval, Jenkins joined other agency top officials in arguing that Sarepta never came close to providing clear evidence of the drug’s safety and efficacy. He clashed with Woodcock over that position, ultimately essentially accusing her of appearing to be biased and browbeating medical reviewers, Endpoint reports. He retired from FDA months after losing the debate.